

**Review Form 3**

Journal Name:	<a href="#">International Journal of Biochemistry Research &amp; Review</a>
Manuscript Number:	Ms_IJBCRR_130577
Title of the Manuscript:	Elucidating the ocular benefits of Haritaki: Phytochemical analysis of Terminalia chebula compounds for Myopia and other Therapeutic uses using in vitro and in silico approaches
Type of the Article	Research

**General guidelines for the Peer Review process:**

This journal’s peer review policy states that **NO** manuscript should be rejected only on the basis of ‘**lack of Novelty**’, provided the manuscript is scientifically robust and technically sound. To know the complete guidelines for the Peer Review process, reviewers are requested to visit this link:

<https://r1.reviewerhub.org/general-editorial-policy/>

**Important Policies Regarding Peer Review**

Peer review Comments Approval Policy: <https://r1.reviewerhub.org/peer-review-comments-approval-policy/>  
Benefits for Reviewers: <https://r1.reviewerhub.org/benefits-for-reviewers>

Review Form 3

PART 1: Comments

	Reviewer's comment	Author's Feedback <i>(Please correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)</i>
Please write a few sentences regarding the importance of this manuscript for the scientific community. A minimum of 3-4 sentences may be required for this part.	Myopia can sometimes be exacerbated by inflammation and oxidative stress within ocular tissues. The anti-inflammatory properties of <i>Terminalia chebula</i> can help mitigate these effects by reducing oxidative stress and promoting tissue repair. The in silico ADME evaluation and docking analysis of <i>Terminalia chebula</i> extracts highlight the drug-likeness and therapeutic potential of its compounds. Docking studies performed indicate significant binding interactions of Naratriptan N-Oxide from the Ethyl Acetate extract with 5AER, Tridecane from the Hexane extract and Doxylamine from the Methanol extract with 5DSG. Additionally, the ethyl acetate extract's 7-Chloro-6-[4-(diethylamino)phenyl]-5,8-quinolinedione shows the highest binding affinity for 1BY4, supporting its potential in treating eye disorders. These analyses highlight several promising ligands with favorable drug-like properties and strong target interactions, indicating the need for further pre-clinical studies to confirm their therapeutic potential.	All the suggested comments have been taken into consideration and necessary changes have been made. The modifications have been highlighted in the revised manuscript document.
Is the title of the article suitable? (If not please suggest an alternative title)	Yes	Thanks for the comments
Is the abstract of the article comprehensive? Do you suggest the addition (or deletion) of some points in this section? Please write your suggestions here.	Yes	Thanks for the comments
Is the manuscript scientifically, correct? Please write here.	Yes	
Are the references sufficient and recent? If you have suggestions of additional references, please mention them in the review form.	Yes . Add some more recent references.	I have added some recent references and highlighted them.
Is the language/English quality of the article suitable for scholarly communications?	yes	
Optional/General comments	Spacing must be corrected in the entire manuscript.	I have corrected the spacing in the entire manuscript.

PART 2:

	Reviewer's comment	Author's comment <i>(if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)</i>
Are there ethical issues in this manuscript?	<i>(If yes, Kindly please write down the ethical issues here in details)</i>	